CD274 and cancer: Nevertheless, immune checkpoint therapies and combinations of multiple agents have provided robust evidence of their benefits to clinical patients and have the potential to elicit durable control, and even curing, of cancer.413–415 (v) Based on the current understanding of immune therapy causing checkpoint blockade, factors that can activate T cells and increase immune checkpoints, such as PD-1/PD-L1 and CLTA-4,are promising agents for future application.